Tisotumab vedotin
Based on 1 Customer Validation
Tisotumab vedotin is an antibody drug conjugate (ADC) targeting tissue factor (TF), formed by covalently linking a fully human monoclonal antibody (TF-011) against TF with the microtubule disruptor Monomethyll Auristatin E (MMAE) (HY-15162), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Tisotumab vedotin has immunomodulatory and anti-tumor activities, and can be used in the study of advanced or metastatic solid tumors such as cervical cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.87%
- CAS 番号: 1418731-10-8
- 分子量:152000 (average)
-
保管条件:
-80°C, protect from light
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
HY-141601
Telisotuzumab vedotinAnti-c-MET ADC -
HY-P99107A
Brentuximab vedotin (solution)ADC -
HY-132253
Polatuzumab vedotinMicrotubule Inhibitor -
HY-138298A
Trastuzumab deruxtecanHER2 ADC -
HY-P9921
Trastuzumab emtansineAntibody-drug Conjugate -
HY-P9985
Disitamab vedotinHER2-Directed ADC -
HY-141598
Datopotamab deruxtecan (solution)TROP2-Targeted ADC -
HY-P3239
Belantamab mafodotinAnti-BCMA ADC -
HY-132254
Sacituzumab govitecanTrop-2 ADC -
HY-132258A
Mirvetuximab soravtansine (solution)ADC -
HY-P99813
Patritumab deruxtecanHER3-Directed ADC -
HY-138298
Trastuzumab deruxtecan (solution)HER2 ADC
生物活性
製品説明
IC50 & Target
tissue factor[1].
体外実験
Tisotumab vedotin induces immunogenic cell death in tumor cells expressing TF, leading to the release of endoplasmic reticulum stress markers, ATP, and high mobility histone B1 (HMGB1)[1]. Tisotumab vedotin induces anti-tumor activity through MMAE mediated cytotoxicity, Fc mediated antibody dependent cell phagocytosis (ADCP), and Fab mediated protease activated receptor 2 (PAR-2) signaling inhibition[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:HPAF-II, SCID mice[4].
-
Dosage:2 mg/kg
-
Administration:Once daily; 25 days
-
Result:Decreased the tumor volume over the 3-week window.
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 1418731-10-8
-
性状 Liquid
-
分子量 152000 (average)
-
Color Colorless to light yellow
-
SMILES
[Tisotumab vedotin]
-
輸送条件
Shipping with dry ice.
-
保管条件
-80°C, protect from light
純度とドキュメンテーション
-
データシート (273 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
取扱説明書 (2659 KB)
参考文献
[3]. Luu K, et al. A review of the novel tissue factor antibody-drug conjugate: Tisotumab vedotin. J Oncol Pharm Pract. 2023 Mar;29(2):441-449. [Content Brief]
[4]. Rubahamya B, et al. Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data. Sci Adv. 2024 May 31;10(22):eadk1894. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Tisotumab vedotin 関連分類
HY-152963 関連分類
Powered by Bioz